Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

Plaque psoriasis affects millions worldwide and is characterized by inflamed, scaly plaques on the skin. VYNE's BET inhibitors aim to offer a non-biologic treatment option that could manage the ...

Oruka Therapeutics is developing novel biologics designed to set a new standard ... suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition ...

A healthcare provider may recommend topical medications (those applied to the skin), oral medications, or newer biologic ...

Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis ... provide a non-biologic ...

Plaque psoriasis affects millions worldwide and is characterized by inflamed, scaly plaques on the skin. VYNE's BET inhibitors aim to offer a non-biologic treatment option that could manage the ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...

Tremfya is a biologic and belongs to a drug class called interleukin-23 blockers. The medication is not available in a biosimilar version. Read on for more information about Tremfya. You can also ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...

Vowst contains the active ingredient fecal microbiota spores, live-brpk, and it’s available only as a brand-name biologic drug. It doesn’t come in a biosimilar version. A biosimilar medication ...